Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2019 | Volume: 15 | Issue: 4 | Page No.: 465-477
DOI: 10.3923/ijp.2019.465.477
Nanoparticles Ellagic Acid Protects Against Cisplatin-induced Hepatotoxicity in Rats Without Inhibiting its Cytotoxic Activity
Nagla Abd El-Aziz El-Shitany , Aymn Tallat Abbas, Soad Shaker Ali , Basma Eid , Steve Harakeh, Thikryat Neamatallah, Ahmed Al-Abd and Shaker Mousa

Abstract:
Background and Objective: Ellagic acid (ELL) is a phenolic constituent of natural sources with antioxidant and anti-inflammatory activities. The ELL has a low bio-availability, therefore a nanoparticles (NP ELL) was formulated to determine whether NP ELL could alleviate cisplatin (CISP)-induced hepatotoxicity in comparison to a high dose of regular ELL. Materials and Methods: The NP ELL was prepared using an emulsion solvent diffusion technique. Hepatotoxicity was induced in rats using CISP (7.5 mg kg–1). Rats were pre-treated with either 10 ELL (10 mg kg–1), 1 NP ELL (1 mg kg–1) or 2 NP ELL (2 mg kg–1). Results: All ELL regimens significantly decreased CISP-induced increases in liver enzymes, MDA, NO, TNF-α, NFkB and BAX. Additionally, all significantly restored hepatic GSH, GPx, CAT and Bcl-2. Rat’s liver showed no injury in all ELL pretreated groups. Importantly, NP ELL did not inhibit the cytotoxic effect CISP against HCT116 cell lines. Conclusion: The NP ELL has improved bio-availability and protected against CISP induced hepatotoxicity. This provides an encouraging way of ameliorating the bio-availability of ELL while sustaining its desirable therapeutic effects.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Nagla Abd El-Aziz El-Shitany, Aymn Tallat Abbas, Soad Shaker Ali, Basma Eid, Steve Harakeh, Thikryat Neamatallah, Ahmed Al-Abd and Shaker Mousa, 2019. Nanoparticles Ellagic Acid Protects Against Cisplatin-induced Hepatotoxicity in Rats Without Inhibiting its Cytotoxic Activity. International Journal of Pharmacology, 15: 465-477.

DOI: 10.3923/ijp.2019.465.477

URL: https://scialert.net/abstract/?doi=ijp.2019.465.477

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

       

       

Curve Bottom